Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vestipitant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 known ✓ | P25103 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vestipitant SCHEMBL14336089 | 1.00 | TACR1 (1.00) | TACR1CYP3A4SIGMAR1 | |
| Vestipitant SCHEMBL29447787 | 1.00 | TACR1 (1.00) | TACR1CYP3A4SIGMAR1 | |
| Vestipitant SCHEMBL2487615 | 1.00 | TACR1 (1.00) | TACR1CYP3A4SIGMAR1 | |
| Vestipitant SCHEMBL14335197 | 0.96 | TACR1 (0.92) | TACR1CYP3A4SIGMAR1 | |
| Vestipitant SCHEMBL14335764 | 0.96 | TACR1 (0.92) | TACR1CYP3A4SIGMAR1 | |
| Vestipitant SCHEMBL14335426 | 0.95 | TACR1 (0.90) | TACR1CYP3A4SIGMAR1 | |
| Vestipitant SCHEMBL14335424 | 0.95 | TACR1 (0.90) | TACR1CYP3A4SIGMAR1 | |
| SCHEMBL6546058 | 0.93 | TACR1 (0.86) | TACR1CYP3A4SIGMAR1 | |
| SCHEMBL2487012 | 0.92 | TACR1 (0.85) | TACR1 | |
| SCHEMBL16888843 | 0.92 | TACR1 (0.84) | TACR1CYP3A4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 323 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4683713-A1 | DEUTERATED P2X3 MODULATORS | GlaxoSmithKline Intellectual Property (No.3) Limited (GB) | 2026-01-28 | — | — | EP | claimed |
| EP-4255400-B1 | NEUROKININ INHIBITORS SUCH AS APREPITANT FOR TREATING NON SMALL CELL LUNG CARCINOMA WITHOUT MUTATIONS | PLUS VITECH S L (ES) | 2025-12-24 | — | — | EP | claimed |
| US-12419861-B2 | Method for preventing and/or treating chronic traumatic encephalopathy-i | EUSTRALIS PHARMACEUTICALS LIMITED (TRADING AS PRESSURA NEURO) (AU) | 2025-09-23 | — | — | US | claimed |
| US-12390454-B2 | Use and composition for protection against organophosphorus poisoning | CLARENCE SMITH KATHLEEN E (US) | 2025-08-19 | — | — | US | claimed |
| US-20250082625-A1 | NOVEL THERAPY | SELECTIMMUNE PHARMA AB (SE) | 2025-03-13 | — | — | US | claimed |
| EP-2966448-B1 | METHOD FOR THE PREDICTION OR PROGNOSIS OF THE RESPONSE OF A HUMAN SUBJECT SUFFERING FROM CANCER TO TREATMENT WITH AN ANTAGONIST OF THE NK1 RECEPTOR | SERVICIO ANDALUZ DE SALUD (ES) | 2025-03-05 | — | — | EP | claimed |
| EP-4461362-A2 | NK1-ANTAGONIST COMBINATION AND METHOD FOR TREATING SYNUCLEINOPATHIES | Chase Therapeutics Corporation (US) | 2024-11-13 | — | — | EP | claimed |
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2024-11-07 | — | — | US | claimed |
| WO-2024194352-A1 | DEUTERATED P2X3 MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2024-09-26 | — | — | WO | claimed |
| US-20240299404-A1 | TREATMENT OF PRURITUS WITH P2X3 MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2024-09-12 | — | — | US | claimed |
| EP-4103564-A1 | P2X3 MODULATORS | Bellus Health Cough Inc. (CA) | 2022-12-21 | — | — | EP | claimed |
| WO-2022253748-A1 | COMBINATIONS FOR THE TREATMENT OF HPV | Plus Vitech, S.L. (ES) | 2022-12-08 | — | — | WO | claimed |
| WO-2022243430-A1 | TREATMENT OF ACNE | Plus Vitech, S.L. (ES) | 2022-11-24 | — | — | WO | claimed |
| US-20220331284-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS UTILIZING NEOSTIGMINE AND AN NK-1 ANTAGONIST FOR TREATING MYASTHENIA GRAVIS | DAS-MG, INC. | 2022-10-20 | — | — | US | claimed |
| US-11439630-B2 | Use and composition for protection against organophosphorus poisoning | CLARENCE SMITH KATHLEEN E (US) | 2022-09-13 | — | — | US | claimed |
| US-11426384-B2 | Method for preventing and/or treating chronic traumatic encephalopathy-i | EUSTRALIS PHARMACEUTICALS LIMITED (Trading as Pressure Neuro) (AU) | 2022-08-30 | — | — | US | claimed |
| US-20220218663-A1 | METHOD FOR PREVENTING AND/OR TREATING CHRONIC TRAUMATIC ENCEPHALOPATHY-I | EUSTRALIS PHARMACEUTICALS LIMITED (TRADING AS PRESSURA NEURO) (AU) | 2022-07-14 | — | — | US | claimed |
| WO-2022038131-A1 | METHOD FOR THE PREDICTION OF PROGRESSION OR PROGNOSIS OF THE RESPONSE OF A SUBJECT SUFFERING FROM ACUTE ORGAN DAMAGE | Plus Vitech, S.L. (ES) | 2022-02-24 | — | — | WO | claimed |
| US-20220031849-A1 | NANOPARTICLE ENCAPSULATION TO TARGET G PROTEIN-COUPLED RECEPTORS IN ENDOSOMES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-02-03 | — | — | US | claimed |
| US-20200155534-A1 | NOVEL THERAPY | LINNANE PHARMA AB (SE) | 2020-05-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | TACR1 670/4885CYP3A4 934/4885SIGMAR1 493/4885 |
| US-20220031849-A1 | NANOPARTICLE ENCAPSULATION TO TARGET G PROTEIN-COUPLED RECEPTORS IN ENDOSOMES | GPR88, GPR65, ARRB1 | TACR1 250/4885CYP3A4 4819/4885SIGMAR1 443/4885 |
| US-20240299404-A1 | TREATMENT OF PRURITUS WITH P2X3 MODULATORS | P2RX3, P2RX1, P2RX5 | TACR1 141/4885CYP3A4 2958/4885SIGMAR1 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.